Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — ZIOPHARM Oncology — JP Morgan 33rd Annual Healthcare Conference 2015
31 slides from Alaunos Therapeutics's conference presentation, Jan 14, 2015
Slide 1: The Future of Cancer Therapy
The Future of Cancer Therapy JP Morgan 33rd Annual Healthcare Conference January2015 www.ziopharm. com
Slide 2: Forward-Looking Statements
Forward_Looking Statements This presentation _ forward contains certain looking information about ZIOPHARM Oncology that is intended to be covered by the safe harbor for “forward Forward looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. looking stateme
Slide 3: JP Morgan - Jonathan Lewis, CEO
JP Morgan Jonathan Lewis, M.D., Ph.D., CEO, ZIOPHARM Oncology www.ziopharm. com
Slide 4: Ad-RTS-IL-12 Overview
Ad_RTS IL 12 Overview Adenoviral Interleukin _ mediated controlled delivery of 12 Oral RTS hIL Ad 12 Oral Activator Activator Distant Tumors Intratumoral Injection Cytotoxic Response Lymphatics IL_12 IF IFNg N Draining Lymph Node ZIOPHARM has leading expertise in clinical translation of designer cyt
Slide 5: Oral Veledimex Precisely Controls the Expression of IL-12
Oral Veledimex Precisely Controls the Expression _IL of 12 ON vp) 6 10000 (mRNA/1e 1000 mRNA 10 or OFF OFF Tum 1 0.1 Baseline Maximum D1 D7 Post 7 Days treatment 100 mg 160 mg n=7 Veledimex Dose
Slide 6: Next Steps for IL-12
Next _ IL steps for 12 Moving to active immunotherapy ZIOPHARM hasleading expertise inclinical translation of designer cytokines RheoSwitch Therapeutic System® platform for conditional expression of _ Immunoreceptors _ Cytokines ZIOPHARM is partnering with MDACC in Boston and Houston
Slide 7: JP Morgan - Greg Frost, Intrexon
JP Morgan Greg Frost, Ph.D., SVP Health Sector, Intrexon Corporation www.ziopharm. com
Slide 8: Non-Viral Adoptive Cellular Therapies
Non_Viral Adoptive Cellular Therapies [Graphic Appears Here] INTREXON and ZIOPHARM Announce Exclusive Licensing Agreement with MD Anderson Cancer Center for Chimeric Antigen Receptor (CAR) T Cell and Associated Technologies for the Development of Non_Viral Adoptive Cellular Therapies
Slide 9: Point of Care and Off-the-Shelf Cellular Solutions
Resulting in Point of Care andOfftheShelf Cellular Solutions PointofCareProduct OfftheShelfProduct “ Integration with RheoSwitch® “ Genetically modify and edit T cells control of T cell propagation and to express CAR and eliminate TCR specificity in patients “ AttSite® landing pads for precision “ F
Slide 10: Key Technology Synergies
Key Technology Synergies Technology Intrexon / ZIOPHARM / MD Anderson RheoSwitch Most advanced family of ligands and switches available Therapeutic System® for dynamic range, safety, and spatial/temporal control Non _ Viral Integration Firstin human testing of Sleeping Beauty system in Platform hema
Slide 11: Reimbursement for Cellular Therapies vs Traditional Oncology
&With Traditional Oncology Reimbursement for Cellular Therapies Avoids Acute PBM Pressures Driven by Cost Density $ ) ( $$$ dule Reimbursement Sche $$ Failure Rate ents Pay $ Cell Reimbursement Days Weeks Months Cell and Ligand Reimbursement Years
Slide 12: JP Morgan - Laurence Cooper, MD Anderson
JP Morgan Laurence J.N. Cooper, M.D., Ph.D., Professor of Pediatrics at MD Anderson
Slide 13: Disclosure of MD Anderson technology license
The technology being discussed has been licensed by MD Anderson to Ziopharm and Intrexon and MD Anderson, which is my employer, will have an equity interest in both companies as a result of the transaction. As an inventor of the licensed technology, I will share in the proceeds of the consideration
Slide 14: Increase in Patient Number Disrupts Manufacturing Scalability
Increase in Patient Number Disrupts Manufacturing Scalability # Patients (Few) Manufacture Tcell T cells Infusion Small Gap
Slide 15: Point of Care and Off the Shelf Manufacturing
Point of Care and Off the Shelf Manufacturing # Patients (Many) Manufacture Tcell T cells Infusion Large Gap Small Gap
Slide 16: Dual CAR T Distribution Approaches
Dual CAR _ Distribution Approaches for T Genetically modified T cells Onepatient Multiple Patients _ Off Specific Autologous T cells Allogeneic T cells the s _ t Patien Real time In advance of need helf (OTS) Disease cure Disease control Point of _ care(POC) _ Centralized Registration Trials & Globa
Slide 17: Steps Toward Point of Care Distribution
Steps Toward Point of Care Distribution T cell Acquisition T cell Manufacturing Time Self Genetic Modification Infusion
Slide 18: Steps Toward Off the Shelf Distribution
Steps Toward Off the Shelf Distribution T cell Acquisition Autologous Donor mpan ies Genetic Modification Co of # Infusion Off the Shelf Allogeneic
Slide 19: Portfolio of Effector Cells
Portfolio of Effector Cells 1. Chimeric Antigen Receptor (CAR+) T cells: Target cell surface tumor associated antigens (TAAs) independent of HLA __Public antigens 2. T Cell Receptor (TCR+) cells: Target intracellular TAAs dependent on HLA __Private antigens 3. Natural Killer (NK) cells: Target tumor
Slide 20: Improving Therapeutic Potential of CAR T Cells
Improving Therapeutic Potential of CART Cells CAR T Cells for improved potency and persistence Understanding ofthe effector cellbiology Co _ stimulation CAR with cytokine Signals 1 & 2 Signal 3
Slide 21: RTS Cell for Gene and Cell-based Therapies
RTS® Cell for Gene and based Therapies + Addition of activator ligand or control solvent _ Withdrawal of activator ligand or control solvent
Slide 22: Building the Next Generation of Inducible Cytokines
Building Next the Generation of Inducible Cytokines Therapeutic potential of effector cells depends on recognition of tumor cells and recycling effector function in tumor microenvironment. Veledimex
Slide 23: Management of Potential Toxicity through Inducible Immunoreceptor Expression
Management of Potential Toxicity through Inducible Immunoreceptor Expression Many attractive target antigens are expressed on normal cells or Veledimex CAR+T Cell ll Inducible orecept CAR+T Cell ll immun TCR+T Cell ll Inducible TCR+T Cell ll nducible I
Slide 24: Advantages of Non-Viral Gene Integration
Advantages Non of Viral Gene Integration Sleeping Beauty transposon/transposase system Efficient andnimblegene transfer method Bypasses the cost, viral time, and complexity of based delivery vectors Transposon (IR/DR) DNA SB Transposase
Slide 25: Manufacturing Platform Defines Specificity & Potency
Manufacturing Platform Defines Specificity & Potency Effector Gene cells insertion Gene editing
Slide 26: Eliminating HLA and TCR on CAR+ T Cells for Universal Donor
Eliminating HLA and TCR on CAR+ T Cells for Universal Donor _ non Recognize _non self_ (Patient ’ Donor) ) TCR±² T cells HLAs HLAs CD19 CAR B _ cell leukemia/lymphoma TCR±² HLAs Healthy donor T cells Re (Donor ’Patient) Artificial nuclease Normal cells Blood. 2013 Aug 22;122(8):1341 9_ Blood. 2012 J
Slide 27: Personalized Therapy for Disease and Patient
Personalized Therapy for Disease and Patient tumor _ Heterogeneity of associated antigen (TAA) Intra Inter tumor tumor Infuse T cells with more than one specificity Infuse T cells with one or more specificity Personalized for the disease Personalized for the patient _N=1_ trial paradigm
Slide 28: ZIOPHARM Oncology
O~ ZIOPHARM Oncology
Slide 29: An Accelerated Synthetic Immunology Pipeline
An Accelerated Synthetic Immunology Pipeline Solid Tumors Point of Off the Care Shelf Myeloid Malignancies B_cell malignancies
Slide 30: An Accelerated Synthetic Immunology Pipeline
An Accelerated Synthetic Immunology Pipeline Compound Pre Clinical Phase 1 Phase 2 Ad-RTS-IL-12 IND Breast/Melanoma GBM CAR/Cytokine Products B-cell malignancies Myeloid Malignancies RTS-controlled T cell Solid Tumors Universal Donor Up to 5 CARs entering clinic in 2015
Slide 31: The Future of Cancer Therapy
The Future of Cancer Therapy JP Morgan 33rd Annual Healthcare Conference January2015 www.ziopharm. com
ZIOPHARM Oncology — JP Morgan 33rd Annual Healthcare Conference 2015 on 6ix